Ace Vision Group Closes Series A Stock Round to Advance Ophthalmic Technologies

Ace Vision Group announced that it closed a Series A preferred stock round totaling $13.3 million ($3.3 million oversubscribed) to continue development and commercialization of its VisioLite Ophthalmic Laser, a touchless therapeutic device being developed for the treatment of age-related vision dysfunction. The company is also in preclinical development of its proprietary procedure, Laser Scleral Microporation (LSM), a minimally invasive rejuvenation procedure for the treatment of presbyopia, glaucoma, and other eye diseases.

“This funding round validates Ace Vision Group’s path forward to explore the potential of Laser Microporation technologies, a new frontier in eye therapy,” Dr. AnnMarie Hipsley, Founder and CEO, said in a company news release. “Our focus is to provide a first-in-class novel therapeutic technology to address and potentially prevent numerous age-related dysfunctions of the eye, which lead to functional vision loss. We are excited to bring this therapeutic technology to patients suffering from presbyopia, which is a vast market with a large unmet need.”

The funding was led by Robert Picerne of Picerne Group, LLC, an Orlando, Florida based enterprise, which provided a substantial portion of the round funding, as well as its venture capital affiliates and a strategic partner.

“The continued support of our primary investors is a strong vote of confidence,” said Joseph Carroll, a member of the Ace Vision Group Board of Directors. “We continue to be impressed with the progress Ace Vision Group has made in developing a fully automated platform to treat age-related conditions in the eye, including presbyopia and glaucoma. The potential of this technology is remarkable and will have many applications for various eye diseases.”

Young American Capital, LLC, a New York based investment capital advisory firm facilitated the Company’s Series A round.